See today's BioWorld Asia
To read the full article sign up for free or sign in.

BMS, Eisai join forces for phase I ADC in potential $3B-plus deal

June 22, 2021
By Randy Osborne
Bristol Myers Squibb Co. and Eisai Co. Ltd. inked a potential $3.1 billion agreement to co-develop and co-commercialize the antibody-drug conjugate MORAb-202 for advanced solid tumors.
BioWorld Asia Deals and M&A Cancer Antibody-drug conjugate Japan